Modeling Diphenhydramine Exposure in Children
Author Information
Author(s): Zamir Ammar, Rasool Muhammad Fawad, Alqahtani Faleh, Alqhtani Hussain, Ahmad Tanveer
Primary Institution: Bahauddin Zakariya University, King Saud University, Najran University, Grenoble Alpes University
Hypothesis
Can a physiologically based pharmacokinetic (PBPK) model predict diphenhydramine exposure in the pediatric population using adult data?
Conclusion
The developed PBPK model accurately predicts diphenhydramine pharmacokinetics in children, highlighting the need for careful dosage monitoring.
Supporting Evidence
- The PBPK model was verified with a 2-fold error in predicted/observed ratios.
- The model showed a 3-fold increase in predicted Cmax for children compared to young adults.
- Findings suggest the need for careful dosage monitoring in pediatric patients.
- The model integrates physiological and ontogeny-related changes in drug metabolism.
- Results indicate that pediatric pharmacokinetics differ significantly from adults.
Takeaway
This study created a computer model to help doctors understand how a common allergy medicine works in kids, so they can give the right amount.
Methodology
The study used literature data to develop a PBPK model for diphenhydramine, comparing predicted and observed pharmacokinetic parameters.
Potential Biases
Potential biases may arise from the reliance on existing literature data and the exclusion of certain populations.
Limitations
The model's accuracy may be affected by the limited availability of pediatric pharmacokinetic data and assumptions made during scaling from adults.
Participant Demographics
The study included healthy children and adolescents aged 2 to 18 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website